INLB — Item 9 Labs Share Price
0.000.00%
Last trade - 00:00- $0.00m
- $33.71m
- $21.76m
- 30
- 89
- 12
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.06% | ||
| Return on Equity | -47.33% | ||
| Operating Margin | -110.94% | ||
Financial Summary
| Year End 30th Sep | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.4 | 4.93 | 8.12 | 21.94 | 21.76 | 23.5 | 30 | 186.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Item 9 Labs Corp. is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The Company also offers a dispensary franchise model through the national Unity Rd. retail brand. The Company offers approximately 75 active cannabis strains and more than 150 differentiated cannabis vaporizer (vape) products, as well as premium concentrates and Orion vape technologies. The Company's Item 9 Labs brand specializes in select products and user experience across several cannabis categories. The Company operates through two segments: Cultivation and Franchising. Its product lines include Item 9 Labs Flower, Item 9 Labs Concentrates, and Orion 710.
Directors
- Douglas Bowden CHM (62)
- Andrew Bowden CEO (34)
- Robert Mikkelsen CFO (40)
- Christopher Wolven COO (40)
- Jeffrey Rassas OTH (59)
- Michael Weinberger DRC (44)
- Eric Kutscher IND (46)
- Lawrence Taylor IND (57)
- Last Annual
- September 30th, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- June 15th, 2010
- Public Since
- November 3rd, 2011
- No. of Shareholders
- 2,904
- No. of Employees
- 97
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 102,362,271
- Address
- 2111 E HIGHLAND AVE, SUITE B375, PHOENIX, 85016
- Web
- https://item9labscorp.com/
- Phone
- +1 4804634246
- Auditors
- BF Borgers CPA PC
Upcoming Events for INLB
Similar to INLB
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
ACI Global
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
FAQ
What is the Item 9 Labs share price?
As of Today at 21:26 UTC, shares in Item 9 Labs are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Item 9 Labs share price performed this year?
Shares in Item 9 Labs last closed at $0.00 and the price had moved by -100% over the past 365 days. In terms of relative price strength the Item 9 Labs share price has underperformed the S&P500 Index by -100% over the past year.
What are the analyst and broker recommendations for Item 9 Labs?
The overall consensus recommendation for Item 9 Labs is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Item 9 Labs dividend yield?
Item 9 Labs does not currently pay a dividend.
Does Item 9 Labs pay a dividend?
Item 9 Labs does not currently pay a dividend.
When does Item 9 Labs next pay dividends?
Item 9 Labs does not currently pay a dividend.
How do I buy Item 9 Labs shares?
To buy shares in Item 9 Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Item 9 Labs?
As of the previous close price of $0.00, shares in Item 9 Labs had a market capitalisation of $0.00m.
Where are Item 9 Labs shares listed?
Here are the trading details for Item 9 Labs:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: INLB
What kind of share is Item 9 Labs?
Based on an overall assessment of its quality, value and momentum Item 9 Labs is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Item 9 Labs share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Item 9 Labs share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Item 9 Labs. Over the past six months, its share price has underperformed the S&P500 Index by -99.97%.
As of the last closing price of $0.00, shares in Item 9 Labs were trading -99.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Item 9 Labs PE Ratio?
The Item 9 Labs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Item 9 Labs?
Item 9 Labs' management team is headed by:
- Douglas Bowden - CHM
- Andrew Bowden - CEO
- Robert Mikkelsen - CFO
- Christopher Wolven - COO
- Jeffrey Rassas - OTH
- Michael Weinberger - DRC
- Eric Kutscher - IND
- Lawrence Taylor - IND